| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/10/2013 | US20130011477 Stable Pharmaceutical Composition of Imatinib |
| 01/10/2013 | US20130011476 Stable compositions of famotidine and ibuprofen |
| 01/10/2013 | US20130011475 Stable compositions of famotidine and ibuprofen |
| 01/10/2013 | US20130011474 Modified and immediate release formulations of memantine |
| 01/10/2013 | US20130011473 Preparation Method Of The Solid Formulation Of Clopidogrel Bisulfate |
| 01/10/2013 | US20130011472 Stable pharmaceutical composition and methods of using same |
| 01/10/2013 | US20130011471 Stable pharmaceutical composition and methods of using same |
| 01/10/2013 | US20130011470 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| 01/10/2013 | US20130011469 Krill oil and carotenoid composition, associated method and delivery system |
| 01/10/2013 | US20130011468 Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| 01/10/2013 | US20130011467 Method of treating malignant solid tumors using transcatheter arterial chemoembolization (tace) |
| 01/10/2013 | US20130011465 Composition and method for the treatment of diseases affected by apoptosis |
| 01/10/2013 | US20130011464 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 01/10/2013 | US20130011462 Melt extruded nicotine thin strips |
| 01/10/2013 | US20130011461 Nicotine-containing chewing gum piece packed in a wrapping of laminate |
| 01/10/2013 | US20130011460 Drug-carrying contact lens and method for fabricating the same |
| 01/10/2013 | US20130011457 Antimicrobial polymers and methods of manufacture thereof |
| 01/10/2013 | US20130011445 Polymer-agent conjugates, particles, compositions, and related methods of use |
| 01/10/2013 | US20130011444 Compositions and methods for overcoming resistance to tramadol |
| 01/10/2013 | US20130011441 TARGETED DELIVERY OF siRNA |
| 01/10/2013 | US20130011433 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 |
| 01/10/2013 | US20130011426 Recombinant Vaccines and Use Thereof |
| 01/10/2013 | US20130011422 Tumor Antigens for the Prevention and/or Treatment of Cancer |
| 01/10/2013 | US20130011417 Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives |
| 01/10/2013 | US20130011411 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 01/10/2013 | US20130011409 Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 |
| 01/10/2013 | US20130011408 Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay |
| 01/10/2013 | US20130011404 Methods and Compositions for Regulating Musashi Function |
| 01/10/2013 | US20130011397 Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain |
| 01/10/2013 | US20130011396 Treatment protocol |
| 01/10/2013 | US20130011392 Method for assessing the ability of a patient to respond to or be safely treated by a nucleoside analog based-chemotherapy |
| 01/10/2013 | US20130011385 Transparent bacterial cellulose nanocomposite hydrogels |
| 01/10/2013 | US20130011379 Pyridoxamine for the Treatment of Diabetic Kidney Disease |
| 01/10/2013 | US20130011377 Compositions, kits and methods for nutrition supplementation |
| 01/10/2013 | US20130011370 Uniform Field Magnetization and Targeting of Therapeutic Formulations |
| 01/10/2013 | US20130011367 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| 01/10/2013 | US20130011365 Parp inhibitor compounds, compositions and methods of use |
| 01/10/2013 | US20130011364 Molecularly imprinted polymers for eliminating metabolites |
| 01/10/2013 | US20130011362 Targeting monomers and polymers having targeting blocks |
| 01/10/2013 | US20130011361 Pyrazole derivatives which modulate stearoyl-coa desaturase |
| 01/10/2013 | US20130011351 Antimycotic pharmaceutical composition |
| 01/10/2013 | US20130011347 Personal Care Compositions With Improved Solubility of a Solid Cosmetic Active |
| 01/10/2013 | US20130011345 Flavor-enhancing amide compounds |
| 01/10/2013 | US20130011344 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells |
| 01/10/2013 | US20130011343 Chewing gum having sustained release of nicotine |
| 01/10/2013 | US20130011342 Surfactant-free, water-free formable composition and breakable foams and their uses |
| 01/10/2013 | US20130011337 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases |
| 01/10/2013 | US20130011333 Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery |
| 01/10/2013 | DE102011078715A1 New substituted pyrazolo-pyridine derivatives useful for treating and/or prophylaxis of e.g. congestive heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular diseases, renal failure, and fibrotic diseases |
| 01/10/2013 | DE102011078699A1 Zufuhr von Substanzen vor der Hämodialysemembran, zB von Acetylcystein, in Dialyseverfahren zur Entfernung des proteingebundenen Toxinen aus dem Blut Delivery of substances before the hemodialysis membrane, eg of acetylcysteine, in dialysis process to remove the protein-bound toxins from the blood |
| 01/10/2013 | CA2844144A1 Rna-yy1 interactions |
| 01/10/2013 | CA2841785A1 Compositions and methods for treatment of symptoms in parkinson's disease patients |
| 01/10/2013 | CA2841229A1 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| 01/10/2013 | CA2841226A1 Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
| 01/10/2013 | CA2841220A1 Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| 01/10/2013 | CA2841214A1 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| 01/10/2013 | CA2840986A1 Treating cancer with hsp90 inhibitory compounds |
| 01/10/2013 | CA2840985A1 Anti-obesity agent comprising high-purity epa |
| 01/10/2013 | CA2840983A1 Adhesive skin patch containing serotonin receptor antagonist drug |
| 01/10/2013 | CA2840932A1 Cough reducing product |
| 01/10/2013 | CA2840918A1 Topical compositions for use in the prevention and/or treatment of dermatitis |
| 01/10/2013 | CA2840907A1 Cannabinoid receptor binding agents, compositions and methods |
| 01/10/2013 | CA2840895A1 Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints |
| 01/10/2013 | CA2840886A1 Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators |
| 01/10/2013 | CA2840883A1 Substituted azaheterocycles for the treatment of cancer |
| 01/10/2013 | CA2840793A1 Drug combinations and uses in treating a coughing condition |
| 01/10/2013 | CA2840763A1 Compounds for the treatment of addiction |
| 01/10/2013 | CA2840754A1 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
| 01/10/2013 | CA2840746A1 Methods of treatment of limited cognitive impairment |
| 01/10/2013 | CA2840620A1 Combination therapy |
| 01/10/2013 | CA2840518A1 Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| 01/10/2013 | CA2840394A1 Voltage-gated sodium channel blockers |
| 01/10/2013 | CA2840222A1 Compositions and methods for treating skeletal myopathy |
| 01/10/2013 | CA2840095A1 Compounds for the treatment of hiv |
| 01/10/2013 | CA2839942A1 Tumor-targeted drug combretastatin a4 derivatives |
| 01/10/2013 | CA2839727A1 Systems, methods, and formulations for treating cancer |
| 01/10/2013 | CA2839584A1 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same |
| 01/10/2013 | CA2839116A1 Cyclic amine derivatives as ep4 receptor antagonists |
| 01/10/2013 | CA2838659A1 Darunavir combination formulations |
| 01/10/2013 | CA2838309A1 Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome |
| 01/10/2013 | CA2838234A1 Oxazepines as ion channel modulators |
| 01/10/2013 | CA2838223A1 Fused benzoxazepinones as ion channel modulators |
| 01/10/2013 | CA2837539A1 Darunavir formulations |
| 01/10/2013 | CA2837524A1 Dihydropyrazoles |
| 01/10/2013 | CA2837247A1 1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
| 01/10/2013 | CA2837047A1 Improvements in or relating to visual performance and/or macular pigmentation |
| 01/10/2013 | CA2835232A1 A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof |
| 01/10/2013 | CA2820977A1 Composition for use in treating and preventing inflammation related disorder |
| 01/09/2013 | EP2543670A1 Pyrazolopyrimidine derivative |
| 01/09/2013 | EP2543669A2 Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| 01/09/2013 | EP2543668A1 Pyridopyrazindione derivative and use thereof as an antiulcer agent |
| 01/09/2013 | EP2543665A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base |
| 01/09/2013 | EP2543664A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/09/2013 | EP2543660A1 Prophylactic or therapeutic agent for diabetes or obesity |
| 01/09/2013 | EP2543390A1 Pharmaceutical composition |
| 01/09/2013 | EP2543385A1 Novel analgesics |
| 01/09/2013 | EP2543378A1 Anticonnexin polynucleotides as impaired wound healing compositions |
| 01/09/2013 | EP2543377A1 Anticonnexin polynucleotides as impaired wound healing compositions |
| 01/09/2013 | EP2543376A1 Benzotriazine inhibitors of kinases |
| 01/09/2013 | EP2543375A1 Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase |